The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
Official Title: Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Study ID: NCT02764593
Brief Summary: This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Stanford Cancer Institute, Palo Alto, California, United States
University of Florida Cancer Center at Orlando Health, Orlando, Florida, United States
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
University of Louisville, Louisville, Kentucky, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
UPMC - Shadyside Hospital, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Inova Fairfax Hospital, Falls Church, Virginia, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Name: Maura Gillison, MD, PhD
Affiliation: RTOG Foundation
Role: PRINCIPAL_INVESTIGATOR
Name: Robert Ferris, MD, PhD
Affiliation: RTOG Foundation
Role: PRINCIPAL_INVESTIGATOR